News

Caretaker Medical Chosen as Finalist to Compete for $350,000 Grand Prize at MedTech Conference

This year brought in a record number of applications with over 1,100 submissions from 54 countries and 42 U.S. states. With less than a 5% acceptance rate, 50 companies were selected to participate in the MedTech Innovator Showcase, with a subset receiving a place in the MedTech Innovator Accelerator. Over four months, 25 Accelerator companies competed for a coveted spot in the Grand Finals. The five finalists are developing medical technology innovations in remote monitoring, patient safety and satisfaction, and prevention:

  • Alva Health (New Haven, CT) is developing a real-time, wearable stroke monitor for older Americans living with high stroke risk.
  • BioDevek (Brookline, MA) is developing an endoscopically-sprayable adhesive hydrogel to seal and protect surgical lesions after polyp removal.
  • Caretaker Medical (Charlottesville, VA ) is developing a wireless finger sensor for continuous “beat by beat” blood pressure and hemodynamics remote monitoring.
  • Cooler Heads Care (San Diego, CA) is developing an affordable wearable device so chemo patients can keep their hair.
  • Nutromics (Brunswick, AUS) is developing a wearable continuous molecular monitoring platform that can track drugs, hormones, metabolites, and proteins.

The final competition will be both live in-person as well as livestreamed on Wednesday, Sept. 29 at 12:00 PM ET during the The MedTech Conference. Viewers will vote online and in-person to decide who takes home the $350,000 Grand Prize and title of MedTech Innovator 2021. Register to watch the competition livestream here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and